Emflaza

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced Friday that the Food and Drug Administration approved a label expansion for the drug Emflaza to include younger patients with Duchenne muscular dystrophy who are between 2 and 5 years old.  PTC Therapeutics shares were trading...